-
GCC market - opportunity to partner in growing market expected to reach US$ 5 billion.
-
Potential for growth - as few GCC generic players.
-
Good group image - AL BAHJA group in Oman and GCC countries, has SBUs spanning various sectors like Agro Products, Chemicals, Solar energy, FMCG, Pharma etc.
-
Group financial strength - assured financial support for pharmaceutical SBU (OPP).
-
Joint Venture advantage - protected and regulated market favourable to MNCs to partner with GCC based generic manufacturing units.
-
Faster registration of company / products - GCC MOH takes less appoval time for dossiers submitted by GCC based generic pharma manufacturing units.
-
Strategically located facility - Salalah plant logistically located near the port for supplies to GCC, Middle East, North Africa & CIS.
-
State-of-the-art validated manufacturing facility.
-
Dedicated manufacturing area - for antibiotics, non-antibiotics, hormones, steroids. Latest machinery, equipments, instruments, systems from reputed suppliers.
-
Unique Strength - only generic company in GCC having facility to manufacture hormones and steroids.
-
Huge production capacity - for all dosage forms like Tablets, Capsules, Liquids, Topicals & Dry powders.
-
Research and formulation development - advanced R&D with ultramodern formulation and analytical equipments.
-
Personnel strength - well qualified and experienced technical and marketing personnel.
-
Future growth plans - product portfolio, facility and marketing operations to be expanded.
-
Regulatory knowledge - Updated with current acceptable documentation and regulatory support.
-
Future business segments - Biotechnology, OTC, Nutraceuticals.
